In the current guidelines issued by the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the International Diabetes Federation (IDF), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended as a first-line therapeutic choice in patients living with type 2 DM (T2DM) who are overweight or obese, particularly in the presence of increased cardiovascular (CV) risk [5,8]. This evidence concerns the gene GLP1R and diabetes mellitus.